SCHEMBL29301548

SCHEMBL29301548

C=C(C)C(C)c1ncccc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PLAU P00749 1/20 0.37
KDM4E B2RXH2 1/20 0.37
FDPS P14324 4/20 0.36
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
IDH1 O75874 1/20 0.34
CYP2D6 P10635 1/20 0.34
HRH1 P35367 1/20 0.34
KCNH2 Q12809 1/20 0.34
HTT P42858 2/20 0.33
CYP2A6 P11509 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SLC6A2 P23975 1/20 0.33
PDK2 Q15119 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3741239 0.78 SMN1; SMN2 (0.42) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL827728 0.78 NOS3 (0.50) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL506508 0.76 NOS3 (0.45) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL29857523 0.76 NOS3 (0.45) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL23343844 0.74 NOS3 (0.46) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL7553930 0.74 NOS3 (0.46) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL4447304 0.74 ALDH1A1 (0.49) NPC1RAB9AKDM4EFDPSMAPT
SCHEMBL23747533 0.72 NOS3 (0.50) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL20482609 0.72 NOS3 (0.50) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL30140878 0.72 NOS3 (0.50) NOS3NOS1NOS2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 NOS3 3076/4885NOS1 4091/4885NOS2 3680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.